Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep:111:61-64.
doi: 10.1016/j.lungcan.2017.07.006. Epub 2017 Jul 11.

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients

Affiliations

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients

Sai-Hong Ignatius Ou et al. Lung Cancer. 2017 Sep.

Abstract

Resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancers (NSCLCs) with activating EGFR mutations generally involve development of acquired secondary or tertiary EGFR mutations, such as T790M or C797S. However, case reports have demonstrated that actionable receptor tyrosine kinase fusions such as EML4-ALK, CCDC6-RET, and FGFR3-TACC3 can potentially confer resistance to EGFR TKIs. We seeked to identify the prevalence of FGFR3-TACC3 fusion transcripts as resistance mechanism to EGFR TKIs. Hybrid-capture based genomic profiling was performed on FFPE tissue samples and circulating tumor DNA isolated from peripheral whole blood in the course of clinical care. We performed a comprehensive survey of 17,319 clinical NSCLC samples (14,170 adenocarcinomas and 3149 NSCLC not otherwise specified (NOS)) and identified 5 cases of FGFR3-TACC3 containing the intact kinase domain of FGFR3 and the coiled-coil domain of TACC3 emerging after treatment with EGFR TKIs, including one previously reported index case. Of the 4 novel cases of FGFR3-TACC3, one emerged after erlotinib, one after afatinib, one after osimertinib, and one after ASP8273. These 5 cases of FGFR3-TACC3 fusions acquired post-EGFR TKI, while rare, indicate that FGFR3-TACC3 is a recurrent resistance mechanism, which can bypass EGFR blockade by all generations of EGFR TKIs in NSCLC. Routine re-biopsy and genomic profiling using platforms capable of detecting kinase fusions has the potential to inform new therapeutic strategies for patients with EGFR-mutant NSCLC progressing on TKIs.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Sai-Hong Ignatius Ou has received speaking and adviser honorarium from Astra Zeneca and Foundation Medicine Inc. Christine M. Lovy has received honorarium from Novartis, Pfizer, ARIAD, Sequenom, Genoptix. Leora Horn has received honorarium from Abbive, X-covery, BMS, Lilly, Merck, and Roche.

Alexa B. Schrock, Adrienne Johnson, Vincent A. Miller, and Siraj M. Ali are employees of Foundation Medicine, Inc. and own stocks in Foundation Medicine, Inc.

Marcelo Cruz, Davood Vafai, Allison Spradlin, Michael J. Williamson, Ibiayi Dagogo-Jack, and Shirish Gadgeel have nothing to declare.

Figures

Fig. 1.
Fig. 1.
(A) Ememrgence of the resistance pulmonary nodules during afatinib treatment and subsequence response to chemotherapy of patient as described in Case 1. Primary tumor response (yellow circle) and no metastatic pulmonary nodules after 7 months of afatinib treatment. Stable pulmonary primary response (yellow circle) but appearance of new pulmonary nodules (yellow arrows) after 16 months of afatinib treatment. Increase in sizes of both primary tumor (yellow circle) and pulmonary nodules (yellow arrows) after 19 months of afatinib treatment.Primary tumor (yellow circle) and metastatic pulmonary nodules (yellow arrows) response to two cycles of chemotherapy. (B) Schematic of the full length FGFR3 and TACC3 genes and the FGFR3-TACC3 fusion variants identified.

References

    1. Sequist LV, Waltman BA, Dias-Santagata D, et al., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci. Transl. Med. 3 (March (75)) (2011) 75ra26. - PMC - PubMed
    1. Yu HA, Arcila ME, Rekhtman N, et al., Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin. Cancer Res. 19 (2013) 2240–2247. - PMC - PubMed
    1. Thress KS, Paweletz CP, Felip E, et al., Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat.Med. 21 (2015) 560–562. - PMC - PubMed
    1. Yu HA, Tian SK, Drilon AE, et al., Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain, JAMA Oncol 1 (2015) 982–984. - PMC - PubMed
    1. Ou SH, Agarwal N, Ali SM, High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression, Lung Cancer 98 (2016) 59–61. - PubMed

MeSH terms

Substances